Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: The PRIME Study

Cerebrovascular Diseases

Volumn 30, Issue 3, 2010, Pages 252-259

  Canouï Poitrine, Florence ^a,b   Luc, Gerald ^c   Bard, Jean Marie ^d   Ferrieres, Jean ^c   Yarnell, John ^e   Arveiler, Dominique ^f   Morange, Pierre ^f   Kee, Frank ^h   Evans, Alun ^h   Amouyel, Philippe ^g   Ducimetiere, Pierre ^c   Empana, Jean Philippe ^a  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f TIMONE HOSPITAL   (France)

^g UNIV LILLE   (France)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Coronary heart disease; Epidemiology; Ischemic stroke; Lipids; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; HAZARD RATIO; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE;

EID: 77954866498     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319067     Document Type: Article

References (34)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
2. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
3. Collins R, Armitage J, Parish S, Sleight P, Peto R: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-767.
4. Amarenco P, Labreuche J, Lavallée P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35: 2902-2909.
5. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829-1839.
6. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108-1113.
7. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
8. Fuentes B, Martínez-Sánchez P, Díez-Tejedor E: Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis 2009; 27(suppl 1):126-133.
9. Ebrahim S, Sung J, Song YM, Ferrer RL, Lawlor DA, Davey Smith G: Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ 2006; 333: 22.
10. Everett BM, Kurth T, Buring JE, Ridker PM: The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol 2006; 48: 2235-2242.
11. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, Cheng JF, Paik MC, Shea S, Berglund L: High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001; 285: 2729-2735.
12. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM: Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004; 63: 1868-1875.
13. Bots ML, Elwood PC, Nikitin Y, Salonen JT, Freire de Concalves A, Inzitari D, Sivenius J, Benetou V, Tuomilehto J, Koudstaal PJ, Grobbee DE: Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 2002; 56 (suppl 1):i19-i24.
14. Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM: Cholesterol and the risk of ischemic stroke. Stroke 2003; 34: 2930-2934.
15. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR: Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003; 34: 623-631.
16. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22: 312-318.
17. Assmann G, Schulte H, Cullen P, Seedorf U: Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest 2007; 37: 925-932.
18. Amarenco P, Steg PG: The paradox of cholesterol and stroke. Lancet 2007; 370: 1803-1804.
19. Ducimetiere P, Ruidavets JB, Montaye M, Haas B, Yarnell J: Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50-59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Int J Epidemiol 2001; 30: 1057-1062.
20. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, Fruchart JC, Ducimetiere P; PRIME Study Group: Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002; 163: 377-384.
21. Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M: Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke 1995; 26: 361-367.
22. Lunn M, McNeil D: Applying Cox regression to competing risks. Biometrics 1995; 51: 524-532.
23. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S: Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224-233.
24. Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, Walldius G, Hellenius ML, Hamsten A: Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2009; 30: 710-717.
25. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS: Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298: 776-785.
26. van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, Khaw KT: Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a casecontrol analysis in EPIC-Norfolk. Ann Intern Med 2007; 146: 640-648.
27. Woodward M, Barzi F, Feigin V, Gu D, Huxley R, Nakamura K, Patel A, Ho S, Jamrozik K: Associations between high-density lipoprotein cholesterol and both stroke and coronary heart disease in the Asia Pacific region. Eur Heart J 2007; 28: 2653-2660.
28. Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, Tanizaki Y, Ibayashi S, Iida M, Kiyohara Y: LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2009; 40: 382-388.
29. Smolders B, Lemmens R, Thijs V: Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 2007; 38: 1959-1966.
30. Amarenco P, Moskowitz MA: The dynamics of statins: from event prevention to neuroprotection. Stroke 2006; 37: 294-296.
31. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME: Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol 2002; 22: 1832-1837.
32. Vivancos-Mora J, Gil-Nunez A: Lipids and stroke: the opportunity of lipid-lowering treatment. Cerebrovasc Dis 2005: 20(suppl 2):53-67.
33. Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A metaregression analysis. J Am Coll Cardiol 2005; 46: 1855-1862.
34. Cui YH, Fan Q, Wang PH, Hui R, Cianflone K, Wang DW: Small dense low-density lipoproteins and associated risk factors in patients with stroke. Cerebrovasc Dis 2009; 27: 99-104.